Skip to main
GH

GH Stock Forecast & Price Target

GH Analyst Ratings

Based on 23 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Guardant Health is positioned as a dominant liquid-biopsy leader with durable franchises in Guardant360, Reveal, and Shield, supported by strong clinical validation, broad NCCN and ACS guideline inclusion, and a large prospective ECLIPSE study. Its outlook is reinforced by accelerating Q1’26 momentum, including $302M revenue, +48% Y/Y growth, 86k oncology tests, a 65% GAAP gross margin, $1.2B of cash, and a raised 2026 revenue guide of $1.30-1.32B. The company also has multiple monetization catalysts ahead, including broader Shield coverage, higher ASPs from reimbursement and ADLT status, and expanding sales reach, which together support sustained double-digit growth and improving profitability.

Bears say

Guardant Health is facing a fundamentally fragile growth story because its upside is concentrated in Shield while its broader franchise remains exposed to slower adoption, reimbursement uncertainty, and a smaller-than-expected market for blood-based screening. Although Q1'26 Shield CRC revenue of about $42M and ~44k volumes beat expectations, the company still depends on Medicare pricing of $1,495/test through YE'27, and margins may compress as it expands beyond that population. Meanwhile, Reveal’s upcoming MRD push enters a crowded market, and the company has burned more than $200M in cash in each of the past two years, with accelerating burn and execution risk around its Q4 2027 breakeven goal.

GH has been analyzed by 23 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardant Health Inc (GH) Forecast

Analysts have given GH a Buy based on their latest research and market trends.

According to 23 analysts, GH has a Buy consensus rating as of Oct 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $189.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $189.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardant Health Inc (GH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.